← Eichor
Condition: Germline Brca Mutated Her2 Negative Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Germline Brca Mutated Her2 Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT05576389Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04090567
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.